Shionogi & Co Ltd

Shionogi’s FY 2026 results show 7.8 % revenue growth and a 17.3 % operating margin, driven by new oncology and immunotherapy launches and cost‑saving digital investments.

Shionogi’s May 12 earnings forecast shows EPS and revenue growth fueled by the RADICAVA acquisition, expanding ALS therapy options and strengthening its rare‑disease portfolio.

Shionogi’s 21% stake in ViiV Healthcare boosts its HIV portfolio, unlocking long‑acting therapies and cost‑efficient manufacturing for a high‑barrier market.

Shionogi’s 2025 results show a strong operating margin driven by a broad‑spectrum antibacterial partnership, with strategic IP, market‑access plans, and M&A options poised to sustain growth amid patent cliffs and fierce competition.

Shionogi partners with Cumulus Neuroscience to boost cognitive drug trials while expanding its antifungal portfolio, positioning itself for growth in high‑potential markets.

Shionogi’s $120 M stake in ViiV Healthcare unlocks global HIV therapy growth, leveraging Japanese distribution to boost sales and secure early access to next‑generation ARTs.

Shionogi & Co., Ltd. remains a stable Japanese pharma firm with strong R&D in antibiotics, rare‑disease drugs, and vaccines, poised for growth amid U.S.–Japan supply‑chain collaboration.

Shionogi & Co.: Japan’s quietly stable pharma firm prioritises long‑term R&D, low leverage, and PMDA‑friendly compliance—offering a value‑investor‑friendly platform for future breakthroughs.

Shionogi expands ALS R&D and global reach, partnering with Salubritas and securing Radicava® rights—boosting science, market share, and investor confidence.

Shionogi & Co. maintains a stable financial position, with a steady stock price and moderate valuation, solidifying its position as a stalwart in the pharmaceutical industry.